Clinical Trial Update: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of VCAR33, a donor-derived anti-CD33 CAR T-cell therapy, in relapsed or refractory acute myeloid leukemia after allogeneic hematopoietic cell tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• VCAR33 (Anti-CD33 CAR T cell therapy)

Snippet

Sponsor: Vor Biopharma | Conditions: Leukemia, Myeloid, Acute | Phase 1, Phase 2 | Status: TERMINATED